Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
The Chosun Ilbo on MSN
Eye drops, pills challenge injections in macular degeneration
Macular degeneration, cited as the leading cause of blindness in the elderly, is driving rapid growth in the treatment market ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
Regeneron Pharmaceuticals (REGN Quick Quote REGN - Free Report) announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients ...
FRANKFURT, Nov 10 (Reuters) - Bayer (BAYGn.DE), opens new tab said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a ...
ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results